NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

FATE

Fate Therapeutics Inc

Jul 03 • 04:00PM ET

1.12

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD CRSP BLUE SRPT EDIT NTLA CLLS SGMO TVRD VTVT

| Held by: VTI IWM VXF IWN IBB DFAT VTWO SCHA VHT DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.49	Insider Own	6.58%	Shs Outstand	114.60M	Perf Week	1.82%
Market Cap	128.39M	Forward P/E	-	EPS next Y	-1.30	Insider Trans	-0.27%	Shs Float	107.09M	Perf Month	-17.65%
Enterprise Value	-28.71M	PEG	-	EPS next Q	-0.35	Inst Own	84.22%	Short Float	8.88%	Perf Quarter	45.45%
Income	-175.88M	P/S	9.62	EPS this Y	18.24%	Inst Trans	-6.17%	Short Ratio	4.51	Perf Half Y	-30.86%
Sales	13.34M	P/B	0.45	EPS next Y	3.38%	ROA	-36.32%	Short Interest	9.51M	Perf YTD	-32.12%
Book/sh	2.52	P/C	0.53	EPS next 5Y	9.93%	ROE	-49.23%	52W High	5.92 -81.08%	Perf Year	-65.64%
Cash/sh	2.10	P/FCF	-	EPS past 3/5Y	9.89% -2.63%	ROIC	-48.16%	52W Low	0.66 69.43%	Perf 3Y	-95.47%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-37.51% 5.00%	Gross Margin	-31.04%	Volatility	9.03% 10.36%	Perf 5Y	-96.69%
Dividend TTM	-	EV/Sales	-2.15	EPS Y/Y TTM	22.13%	Oper. Margin	-1392.96%	ATR (14)	0.12	Perf 10Y	-81.73%
Dividend Ex-Date	-	Quick Ratio	8.81	Sales Y/Y TTM	105.85%	Profit Margin	-1318.93%	RSI (14)	44.34	Recom	2.36
Dividend Gr. 3/5Y	- -	Current Ratio	8.81	EPS Q/Q	33.07%	SMA20	-11.48%	Beta	2.24	Target Price	5.36
Payout	-	Debt/Eq	0.29	Sales Q/Q	-15.38%	SMA50	-8.08%	Rel Volume	0.58	Prev Close	1.12
Employees	181	LT Debt/Eq	0.27	Earnings	May 13 AMC	SMA200	-36.19%	Avg Volume	2.11M	Price	1.12
IPO	Oct 01, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	16.51% 52.81%	Trades		Volume	1,213,797	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-24	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-24	Upgrade	Piper Sandler	Neutral → Overweight	$4 → $6
Mar-27-23	Resumed	Wells Fargo	Equal Weight	$6
Jan-24-23	Downgrade	H.C. Wainwright	Buy → Neutral	$115 → $7
Jan-06-23	Downgrade	Wedbush	Outperform → Neutral	$42 → $7
Jan-06-23	Downgrade	Truist	Buy → Hold	$46 → $7
Jan-06-23	Downgrade	Stifel	Buy → Hold	$107 → $5.30
Jan-06-23	Downgrade	Piper Sandler	Overweight → Neutral	$71 → $12
Jan-06-23	Downgrade	Cowen	Outperform → Market Perform
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform	$72 → $4
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$20 → $7
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Dec-15-22	Initiated	Goldman	Sell	$10
Nov-04-22	Resumed	Cantor Fitzgerald	Overweight	$98 → $45
Oct-10-22	Initiated	Canaccord Genuity	Buy	$42
Aug-18-22	Resumed	Wells Fargo	Overweight	$90
Jul-28-22	Initiated	Needham	Hold
Jul-11-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$50 → $47
Jun-03-22	Initiated	Robert W. Baird	Neutral	$28

Show Previous Ratings

Jul-03-25 01:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-12-25 11:30AM	Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? (Zacks) -9.68%
Jun-11-25 09:00AM	Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress (GlobeNewswire) -7.19%
Jun-10-25 10:23AM	Top Cancer Stocks to Supercharge Your 2025 Portfolio (Zacks) +9.87%
May-30-25 04:30PM	Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors (GlobeNewswire) -8.33% +7.44%
11:46PM	Loading…
May-28-25 11:46PM	Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune Diseases (Insider Monkey)
05:54PM	Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress (GlobeNewswire)
May-14-25 11:41AM	Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus (Zacks)
May-13-25 05:15PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.54%
04:01PM	Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
May-02-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.65% -10.69%
Apr-29-25 09:25AM	Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting (GlobeNewswire) -6.40%
Apr-15-25 10:42AM	Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag (Zacks) +21.17%
Apr-14-25 08:00AM	Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) (GlobeNewswire) -12.80%
Apr-04-25 11:30AM	Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound? (Zacks) +10.72%
04:01PM	Loading…
Apr-02-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.69%
Mar-05-25 05:10PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +14.90%
04:12PM	Fate Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates (GlobeNewswire)
Mar-04-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.77%
Feb-17-25 10:00AM	Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know (Zacks)
Feb-14-25 04:01PM	Fate Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +11.81% +7.75%
Feb-04-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.40%
Jan-03-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-12-24 11:30AM	Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue? (Zacks) -11.70%
Dec-09-24 04:01PM	Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus (GlobeNewswire) -16.18%
Dec-03-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.15%
Dec-02-24 09:55AM	Fate Therapeutics makes Bob Valamehr president and CEO (Pharmaceutical Technology) -6.62%
Nov-29-24 01:05PM	Fate Therapeutics Announces Leadership Transition (GlobeNewswire)
Nov-26-24 04:01PM	Fate Therapeutics to Present at Upcoming December Investor Conferences (GlobeNewswire) +10.74% +18.28%
08:05AM	Loading…
Nov-18-24 08:05AM	Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence (GlobeNewswire) +12.38%
08:00AM	Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence (GlobeNewswire)
Nov-12-24 05:20PM	Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.03% -8.82%
04:18PM	Fate Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Nov-09-24 01:30PM	Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting (GlobeNewswire)
Nov-08-24 04:01PM	Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting (GlobeNewswire) -5.10% +5.79%
Nov-04-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.58%
Oct-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-12-24 04:01PM	Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference (GlobeNewswire) +7.49%
11:30AM	Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report? (Zacks)
Aug-16-24 12:00PM	All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy (Zacks)
Aug-13-24 05:25PM	Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:25PM	Fate Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Aug-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.12% -9.50%
Jul-31-24 08:00AM	Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors (GlobeNewswire)
Jul-21-24 05:37AM	Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? (Motley Fool)
Jul-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 04:01PM	Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-24 10:48AM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 02:50PM	Fate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial Performance Amid Clinical ... (GuruFocus.com)
10:36AM	Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating (MT Newswires)
08:22AM	Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating (MT Newswires)
May-09-24 08:58PM	FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.41%
05:25PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:21PM	Fate Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
08:30AM	Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program (GlobeNewswire)
May-06-24 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates (GlobeNewswire)
May-03-24 04:30PM	Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting (GlobeNewswire)
Apr-22-24 04:30PM	Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting (GlobeNewswire) -5.02%
Apr-06-24 02:17AM	Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress (Zacks)
Apr-04-24 11:30PM	NOTICE TO LONG-TERM SHAREHOLDERS OF FATE THERAPEUTICS, INC. (FATE): GRABAR LAW OFFICE IS INVESTIGATING CLAIMS ON YOUR BEHALF (Newsfile)
Apr-03-24 08:00AM	Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-24 11:30AM	Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound? (Zacks) +7.00%
Mar-19-24 08:44AM	Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement (GlobeNewswire)
Mar-05-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.15%
Mar-01-24 08:09AM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.17%
08:00AM	Fate Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Feb-27-24 09:16AM	Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y (Zacks) +7.34%
08:07AM	Q4 2023 Fate Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-24 05:10PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:35PM	Fate Therapeutics Inc (FATE) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
04:08PM	Fate Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates (GlobeNewswire)
Feb-21-24 09:21AM	13 Best Booming Stocks to Buy Right Now (Insider Monkey)
Feb-19-24 10:00AM	Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Feb-15-24 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +9.09%
Feb-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-30-24 07:54AM	Fate Therapeutics (FATE) Soars 25.4%: Is Further Upside Left in the Stock? (Zacks)
Jan-29-24 02:53PM	Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock (InvestorPlace) +25.44%
Jan-08-24 08:00AM	Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors (GlobeNewswire) +9.28%
Dec-22-23 12:00PM	Fate Therapeutics (FATE) Upgraded to Buy: Here's Why (Zacks)
Dec-18-23 02:58PM	12 Most Promising Cancer Stocks According to Analysts (Insider Monkey)
Dec-13-23 05:00PM	Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.67% +11.19%
Dec-08-23 11:30AM	Fate Therapeutics (FATE) Up 10.3% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-09-23 01:18PM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2023 Earnings Call Transcript (Insider Monkey) -8.58%
Nov-08-23 06:18PM	Fate Therapeutics Inc (FATE) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
04:08PM	Fate Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Oct-25-23 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results (GlobeNewswire) -7.22%
Sep-15-23 06:01AM	Strength Seen in Mirum Pharmaceuticals, Inc. (MIRM): Can Its 8.0% Jump Turn into More Strength? (Zacks) -6.78%
Sep-07-23 11:30AM	Why Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report? (Zacks)
Aug-31-23 08:00AM	Fate Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-29-23 07:30AM	16 Most Shorted Stocks Right Now (Insider Monkey)
Aug-09-23 12:12PM	FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss (Zacks)
11:04AM	Q2 2023 Fate Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wolchko J Scott	Former Officer and Director	Mar 06 '25	Proposed Sale	0.93	113,178	104,881		Mar 06 01:52 PM
Bressi Jerome Charles	See Remarks	Jan 10 '25	Sale	1.55	5,980	9,269	270,203	Jan 13 04:06 PM
TAHL CINDY	See Remarks	Jan 10 '25	Sale	1.55	5,654	8,764	336,707	Jan 13 04:05 PM
Valamehr Bahram	President and CEO	Jan 10 '25	Sale	1.54	8,705	13,406	349,364	Jan 13 04:04 PM
Valamehr Bahram	Officer	Jan 10 '25	Proposed Sale	1.54	8,705	13,447		Jan 10 03:20 PM
Bressi Jerome Charles	Officer	Jan 10 '25	Proposed Sale	1.55	5,980	9,276		Jan 10 03:12 PM
TAHL CINDY	Officer	Jan 10 '25	Proposed Sale	1.55	5,654	8,782		Jan 10 03:12 PM
Redmile Group, LLC	Director	Dec 20 '24	Buy	1.68	397,964	668,580	12,884,277	Dec 26 09:00 PM
Redmile Group, LLC	Director	Dec 20 '24	Sale	1.68	341,633	573,943	12,486,313	Dec 26 09:00 PM
Redmile Group, LLC	Director, 10% Stockholder	Dec 20 '24	Proposed Sale	1.66	341,633	567,111		Dec 20 09:00 PM
Xu Yuan	Director	Aug 06 '24	Sale	4.23	633	2,678	8,669	Aug 07 04:01 PM
Xu Yuan	Director	Aug 06 '24	Proposed Sale	4.23	633	2,678		Aug 06 10:34 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FATE

Fate Therapeutics Inc

Upgrade your FINVIZ experience